Editas Medicine and Beam Therapeutics rally on rumored deal

Aug. 06, 2020 7:38 AM ETEditas Medicine, Inc. (EDIT), BEAM, CRSP, NTLAEDIT, NTLA, CRSP, BEAMBy: Douglas W. House, SA News Editor16 Comments
  • CRISPR/Cas9 gene editor Editas Medicine (NASDAQ:EDIT) and modified CRISPR gene editor Beam Therapeutics (NASDAQ:BEAM) are up 21% and 35%, respectively, premarket on chatter that a deal is imminent.
  • Developing....
  • Other CRISPR stocks to watch: CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics (NASDAQ:NTLA)
  • Update: Both companies have declined to comment on the speculation.

Enterprise value of EDIT and BEAM

Recommended For You

Comments (16)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.